Atea Pharmaceuticals (AVIR)
(Real Time Quote from BATS)
$3.64 USD
-0.18 (-4.71%)
Updated Sep 20, 2024 12:22 PM ET
2-Buy of 5 2
B Value C Growth A Momentum B VGM
Income Statements
Fiscal Year end for Atea Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 351 | 49 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 351 | 49 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 164 | 131 | 213 | 60 | 15 |
Income After Depreciation & Amortization | -164 | -131 | 138 | -11 | -15 |
Non-Operating Income | 29 | 11 | 0 | 0 | 1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -135 | -120 | 139 | -11 | -14 |
Income Taxes | 1 | -4 | 17 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -136 | -116 | 121 | -11 | -14 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -136 | -116 | 121 | -11 | -14 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -179 | -136 | 138 | -11 | -15 |
Depreciation & Amortization (Cash Flow) | -15 | -5 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -164 | -131 | 138 | -11 | -15 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 83.39 | 83.25 | 88.25 | 21.59 | NA |
Diluted EPS Before Non-Recurring Items | -1.63 | -1.39 | 1.37 | -0.51 | NA |
Diluted Net EPS (GAAP) | -1.63 | -1.39 | 1.37 | -0.51 | NA |
Fiscal Year end for Atea Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 46.92 | 69.81 | 46.58 | 40.78 | 35.23 |
Income After SG&A, R&D, and Dept/Amort Expenses | -46.92 | -69.81 | -46.58 | -40.78 | -35.23 |
Non-Operating Income | 6.64 | 6.87 | 7.76 | 7.86 | 7.30 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -40.28 | -62.94 | -38.82 | -32.92 | -27.93 |
Income Taxes | 0.24 | 0.23 | 0.35 | 0.22 | 0.25 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -40.52 | -63.17 | -39.16 | -33.14 | -28.18 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -40.52 | -63.17 | -39.16 | -33.14 | -28.18 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 84.25 | 83.92 | 83.44 | 83.40 | 83.40 |
Diluted EPS Before Non-Recurring Items | -0.48 | -0.75 | -0.47 | -0.40 | -0.34 |
Diluted Net EPS (GAAP) | -0.48 | -0.75 | -0.46 | -0.40 | -0.34 |